Osimertinib launched for lung cancer patients with EGFR resistance mutation

Osimertinib (Tagrisso) is now available for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumours have a specific mutation in the epidermal growth factor receptor (EGFR) gene that is associated with resistance to other EGFR inhibitors.

EGFR mutations are found in 10–15% of NSCLC patients in Europe and 30–40% of NSCLC patients in Asia. | SCIENCE PHOTO LIBRARY
EGFR mutations are found in 10–15% of NSCLC patients in Europe and 30–40% of NSCLC patients in Asia. | SCIENCE PHOTO LIBRARY

Osimertinib targets oncogenic mutant forms of EGFR, including those harbouring the T790M mutation that is commonly responsible for the development of resistance to other EGFR inhibitors. The T790M mutation is found in nearly two-thirds of NSCLC patients who experience disease progression after treatment with the EGFR inhibitors gefitinib, erlotinib or afatinib

Tumour responses

Further information
View Tagrisso drug record
Summary of Product Characteristics
Manufacturer: AstraZeneca

The safety and efficacy of osimertinib were demonstrated in two open-label single-arm studies involving a total of 411 patients with advanced EGFR T790M mutation-positive NSCLC whose disease had progressed after treatment with an EGFR inhibitor.

In total, 61% of patients in the first study (AURAex) and 71% of patients in the second study (AURA2) experienced a complete or partial reduction in their tumour size. Responses lasted a median of 7.8 months in AURA2, with a median progression-free survival of 8.6 months (these endpoints were not evaluable for AURAex).

Interstitial lung disease

The most commonly reported adverse reactions to osimertinib were diarrhoea (42%) and rash (24%). Interstitial lung disease occurred in 2.9% of patients and should be excluded in individuals presenting with acute onset and/or unexplained worsening of pulmonary symptoms such as dyspnoea or cough.

Osimertinib is also associated with QT prolongation. Use of the drug should be avoided in patients with congenital long QT syndrome; periodic ECG and electrolyte monitoring should be conducted in patients with congestive heart failure, electrolyte abnormalities, and those who are taking other agents that prolong the QT interval.

Conditional approval

Tagrisso is the first new medicine to be approved under the European Commission's expedited process and authorisation is conditional on further evidence of clinical benefit.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases